Astrazeneca (AZN) Other Non Operating Income (2016 - 2026)

Astrazeneca has reported Other Non Operating Income for 11 years, with the latest figure at -$3.5 billion in Q1 2026.

• On a quarterly basis, Other Non Operating Income fell 10.54% year-over-year to -$3.5 billion in Q1 2026; TTM through Mar 2026 was -$12.5 billion, a 25.83% increase from a year earlier, with the FY2023 full-year figure at -$7.9 billion, down 3831.0% from the prior year.
• Other Non Operating Income was -$3.5 billion for Q1 2026 at Astrazeneca, down from -$3.2 billion in the prior quarter.
• The five-year high for Other Non Operating Income was -$2.1 billion in Q1 2022, with the low at -$7.9 billion in Q4 2023.
• Average Other Non Operating Income over 5 years is -$3.4 billion, with a median of -$2.8 billion recorded in 2024.
• The largest YoY upside for Other Non Operating Income was 31.91% in 2022 against a maximum downside of 24.52% in 2022.
• Over 5 years, Other Non Operating Income stood at -$2.5 billion in 2022, then slumped by 219.85% to -$7.9 billion in 2023, then soared by 60.38% to -$3.1 billion in 2024, then decreased by 1.41% to -$3.2 billion in 2025, then decreased by 10.54% to -$3.5 billion in 2026.
• The last three Other Non Operating Income figures came in at -$3.5 billion (Q1 2026), -$3.2 billion (Q1 2025), and -$3.1 billion (Q3 2024), per Business Quant data.